Latest Conference Articles

December 5th 2016, 4:55am

ASH Annual Meeting and Exposition

Ibrutinib showed an 89% response rate in both treatment-naïve and relapsed patients with chronic lymphocytic leukemia/small lymphocytic lymphoma in findings from the longest follow-up to date for the BTK inhibitor.

December 5th 2016, 3:55am

ASH Annual Meeting and Exposition

Lenalidomide as maintenance following first-line immunochemotherapy substantially improves progression-free survival in the treatment of patients with high-risk chronic lymphocytic leukemia.

December 5th 2016, 2:49am

ASH Annual Meeting and Exposition

The combination of the killer-cell immunoglobulin-like receptors inhibitor lirilumab with the hypomethylating agent azacytidine was well tolerated and showed early signals of activity in heavily pretreated patients with acute myeloid leukemia.

December 5th 2016, 2:48am

ASH Annual Meeting and Exposition

Treatment with enasidenib was active and was well tolerated in pretreated patients with IDH2-mutated myelodysplastic syndrome, including those who failed hypomethylating agents.

December 4th 2016, 11:46pm

ASH Annual Meeting and Exposition

Researchers are hopeful that the addition of the investigational agent vadastuximab talirine to standard 7+3 induction therapy may improve survival for patients with acute myeloid leukemia.

December 4th 2016, 12:18pm

ASH Annual Meeting and Exposition

The CAR T-cell therapy CTL019 demonstrated an 82% complete remission (CR) or CR with incomplete blood count recovery rate for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

December 4th 2016, 9:27am

ASH Annual Meeting and Exposition

Mrinal S. Patnaik, MBBS, hematologist, Mayo Clinic, discusses a study investigating SL-401 in patients with myeloproliferative neoplasms during the American Society of Hematology (ASH) Annual Meeting.

December 4th 2016, 8:37am

ASH Annual Meeting and Exposition

Constantine Tam, MD, discusses 2 trials investigating BTK inhibitor BGB-3111 in chronic lymphocytic leukemia (CLL) and Waldenstrom’s macroglobulinemia.

December 4th 2016, 6:42am

ASH Annual Meeting and Exposition

TKIs can safely be stopped or dose-reduced without jeopardizing long-term outcomes for select patients with chronic myeloid leukemia who have obtained a major molecular response.

December 4th 2016, 5:56am

ASH Annual Meeting and Exposition

Brentuximab vedotin induced responses lasting at least 4 months in 56% of patients with cutaneous T-cell lymphoma versus 13% in patients receiving physician’s choice of standard therapies, according to findings from the phase III ALCANZA trial presented at the 2016 ASH Annual Meeting.

December 4th 2016, 4:30am

ASH Annual Meeting and Exposition

CPX-351 may provide a bridge to successful transplantation for older patients with acute myeloid leukemia with limited treatment options.

December 4th 2016, 3:38am

ASH Annual Meeting and Exposition

Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy induced an 80% complete remission rate among children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia, many of whom had prior anti-CD19 CAR T-cell therapy.

December 4th 2016, 2:53am

ASH Annual Meeting and Exposition

The next-generation BTK inhibitor acalabrutinib produced an objective response rate of 38.1% as a monotherapy for patents with Richter transformation.

December 3rd 2016, 11:54pm

ASH Annual Meeting and Exposition

Treatment with the combination of nivolumab and ibrutinib showed encouraging activity and safety in a small phase II study of patients with chronic lymphocytic leukemia and Richter transformation.

November 22nd 2016, 4:15am

Society for Neuro-Oncology Annual Meeting

Manmeet Ahluwalia, MD, FACP, Miller Family Endowed Chair in Neuro-Oncology and Head of Operations, Burkhardt Brain Tumor NeuroOncology Center, discuses a new classification system for brain metastases.

November 22nd 2016, 1:57am

Society for Neuro-Oncology Annual Meeting

Antonio Iavarone, MD, professor of Pathology and Cell Biology and Neurology, Columbia University, Institute for Cancer Genetics, discusses the role of the ID2 protein in patients with malignant brain tumors.

November 20th 2016, 3:23am

Society for Neuro-Oncology Annual Meeting

Researchers are hoping that a proposed phase II study exploring use of the Optune system in patients with recurrent grade III malignant glioma will expand the indications for the tumor treating fields (TTFields) device beyond its current FDA-approved use in recurrent grade IV glioblastoma.

November 20th 2016, 3:08am

Society for Neuro-Oncology Annual Meeting

Treatment with nivolumab and radiotherapy with or without concurrent temozolomide was well tolerated and showed promising signs of efficacy for patients with newly-diagnosed glioblastoma multiforme.

November 20th 2016, 1:39am

Society for Neuro-Oncology Annual Meeting

The PD-L1 inhibitor durvalumab generated durable responses in bevacizumab-naïve patients with recurrent glioblastoma multiforme.

November 20th 2016, 1:25am

Society for Neuro-Oncology Annual Meeting

Treatment with AG-120 at an established dose of 500 mg induced a stable disease rate of 83% and a minor response rate of 9% for patients with non-enhancing IDH1-mutated glioma.